SBIR/STTR Research Award

XRpro Radioactive Cesium Decorporation Agents

Award identifier 771e0313e1f81de16bf3765a3b360a581eb51bec9ebea107fa36b0d21c7416c9Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$600,000

Program and phase

SBIR · Phase I

Award year

2014

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Icagen, Inc.
Proposal award date
2014-07-01
Contract end date
2017-06-30
UEI
Not reported
Solicitation number
PA12-044
Topic code
NIAID

Research abstract

DESCRIPTION provided by applicant Caldera aims to develop an inexpensive stable selective decorporation decorp agent for cesium Cs Cs is easily obtainable by terrorists and treatments for exposures are Project Bioshield priorities for use in radiation nuclear emergencies high priority for DHHS NIH NIAID DAIT and a critical need for the Strategic National Stockpile SNS Calderaandapos s agent will select for Cs over potassium K sodium Na and other elements that are essential for human health Current treatments are non selective and must be used under strict clinical supervision Selectivity is needed because Na and K are more prevalent than Cs in the body non selective decorp agents are swamped by Na and K Na K and Cs have similar properties so selective treatments are traditionally very difficult to develop Agents such as Prussian Blue PB are current treatments for Cs exposure however PB only binds Cs from the gastrointestinal tract GI DTPA analogs have been approved by the FDA for treatment of plutonium americium and curium but they are in intravenous forms so are difficult to administer in response to mass exposure Calderaandapos s approach focuses on chelating radioactive Cs in blood and muscle that has been absorbed systemically from all exposure routes oral dermal inhaled There are no decorp agents to selectively remove Cs from the bloodstream and musculature Caldera will use XRpro r a high throughput screening HTS label free x ray fluorescence XRF technology to produce selective decorp agents for Cs and other radioisotopes XRpro r protocols instruments microarrays and novel ligands increase the signal and decrease the noise for measuring Cs increasing the likelihood that Phase I will result in novel selective Cs decorp agents PUBLIC HEALTH RELEVANCE Caldera aims to develop an inexpensive stable selective decorporation decorp agent for cesium Cs Cs is easily obtainable by terrorists and treatments for exposures are Project Bioshield priorities for use in radiation nuclear emergencies high priority for DHHS NIH NIAID DAIT and a critical need for the Strategic National Stockpile SNS Calderaandapos s agent will select for Cs over potassium K sod ium Na and other elements that are essential for human health Current treatments are non selective and must be used under strict clinical supervision

Technology keywords

Not reported

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.